POLYCLONARL ANTIBODY DIRECTED AGAINST HOMOCYSTEINE THIOLACTONE MODIFIEDLDL

点击翻译按钮获取中文摘要

Homocysteinemia is presumed to be responsible for the development of atherosclerosis, however, the precise etiology is unclear. We examined the possibility that the homocystamide-LDL adduct, a product of the reaction between homocysteine thiolactone and apo-B lysyl residues, was immunogenic. New Zealand white rabbits were immunized with this adduct at 6-week intervals. Antibody titers (ca. 100,000) were determined in antisera collected following the third immunization using solid-phase ELISA techniques. In competition-based ELISAs, homocysteine thiolactone-treated LDL competed for binding with the antiserum, as the 50% inhibitory concentration was approximately 10 micrograms/ml. Neither homocysteine, homocystine, nor Cu(2+)-oxidized LDL competed for binding. LDL in which lysyl residues were derivatized by acetylation or methylation were not recognized by the antiserum. All lipoprotein fractions from homocysteine thiolactone-treated plasma competed for binding to the antiserum. We conclude that homocysteine thiolactone-modified LDL is highly immunogenic and specific for homocystamide-lysyl adducts. This antibody has the potential to be used as a diagnostic tool for measuring plasma homocysteine and for delineating the role of homocysteinemia in vascular disease.